CareDx
Update in progressCDNA (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDiagnostics & Research
CareDx provides transplant-focused diagnostics and software to improve patient outcomes worldwide. Its tests include AlloSure dd-cfDNA for kidney, heart, and lung transplants; AlloMap Heart gene expression profiling; HeartCare and HistoMap Kidney for immune and rejection insights; AlloHeme for relapse prediction in AML/MDS; and a suite of HLA typing, graft monitoring, and transplant management tools (QTYPE, Olerup SSP, AlloSeq Tx/CFDNA/HCT, Allocell, XynQAPI, MedActionPlan, CareDx Pharmacy, AlloHome, HLA Data Systems). licensed with Illumina; founded 1998; Brisbane, CA.
Company score
- Sentiment
- 0.02
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.02
- Governance
- -0.32
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.06
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.02
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!